A citation-based method for searching scientific literature

Nicolas Aide, Laurent Poulain, Nicolas Elie, Mélanie Briand, Florence Giffard, Cécile Blanc-Fournier, Florence Joly, Charline Lasnon. EJNMMI Res 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.
Wolfgang P Fendler, Jeremie Calais, Matthias Eiber, Robert R Flavell, Ashley Mishoe, Felix Y Feng, Hao G Nguyen, Robert E Reiter, Matthew B Rettig, Shozo Okamoto,[...]. JAMA Oncol 2019
217
100

68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
Michael Gabriel, Andreas Oberauer, Georg Dobrozemsky, Clemens Decristoforo, Daniel Putzer, Dorota Kendler, Christian Uprimny, Peter Kovacs, Reto Bale, Irene J Virgolini. J Nucl Med 2009
119
100

Radiation induces up-regulation of somatostatin receptors 1, 2, and 5 in small cell lung cancer in vitro also at low absorbed doses.
Jenny Oddstig, Peter Bernhardt, Ola Nilsson, Håkan Ahlman, Eva Forssell-Aronsson. Cancer Biother Radiopharm 2011
11
100

Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide.
E P Krenning, R Valkema, P P Kooij, W A Breeman, W H Bakker, W W deHerder, C H vanEijck, D J Kwekkeboom, M deJong, S Pauwels. Ital J Gastroenterol Hepatol 1999
53
100

Quantitative Test-Retest Measurement of 68Ga-PSMA-HBED-CC in Tumor and Normal Tissue.
Janet H Pollard, Caleb Raman, Yousef Zakharia, Chad R Tracy, Kenneth G Nepple, Tim Ginader, Patrick Breheny, John J Sunderland. J Nucl Med 2020
10
100

Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes.
John Violet, Price Jackson, Justin Ferdinandus, Shahneen Sandhu, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Sue Ping Thang, Peter Eu,[...]. J Nucl Med 2019
108
100


Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
Marlon Perera, Nathan Papa, Matthew Roberts, Michael Williams, Cristian Udovicich, Ian Vela, Daniel Christidis, Damien Bolton, Michael S Hofman, Nathan Lawrentschuk,[...]. Eur Urol 2020
272
100

Carcinoid tumors.
M H Kulke, R J Mayer. N Engl J Med 1999
600
100

PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis.
Robert Seifert, Katharina Kessel, Katrin Schlack, Manuel Weber, Ken Herrmann, Maximilian Spanke, Wolfgang P Fendler, Boris Hadaschik, Jens Kleesiek, Michael Schäfers,[...]. Eur J Nucl Med Mol Imaging 2021
21
100

Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma.
Michael C Kreissl, Heribert Hänscheid, Mario Löhr, Frederik A Verburg, Markus Schiller, Michael Lassmann, Christoph Reiners, Samuel S Samnick, Andreas K Buck, Michael Flentje,[...]. Radiat Oncol 2012
43
100

68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer.
Alexander Heinzel, Dima Boghos, Felix M Mottaghy, Florian Gaertner, Markus Essler, Dirk von Mallek, Hojjat Ahmadzadehfar. Eur J Nucl Med Mol Imaging 2019
25
100

PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy.
Lisa Bodei, Mark S Kidd, Aviral Singh, Wouter A van der Zwan, Stefano Severi, Ignat A Drozdov, Jaroslaw Cwikla, Richard P Baum, Dik J Kwekkeboom, Giovanni Paganelli,[...]. Eur J Nucl Med Mol Imaging 2018
51
100

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Howard I Scher, Michael J Morris, Walter M Stadler, Celestia Higano, Ethan Basch, Karim Fizazi, Emmanuel S Antonarakis, Tomasz M Beer, Michael A Carducci, Kim N Chi,[...]. J Clin Oncol 2016
618
100

Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody.
N Deb, M Goris, K Trisler, S Fowler, J Saal, S Ning, M Becker, C Marquez, S Knox. Clin Cancer Res 1996
101
100

ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms.
G Delle Fave, D O'Toole, A Sundin, B Taal, P Ferolla, J K Ramage, D Ferone, T Ito, W Weber, Z Zheng-Pei,[...]. Neuroendocrinology 2016
189
100

Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
Neil H Bander, Matthew I Milowsky, David M Nanus, Lale Kostakoglu, Shankar Vallabhajosula, Stanley J Goldsmith. J Clin Oncol 2005
330
100

Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Roelf Valkema, Stanislas Pauwels, Larry K Kvols, Raffaella Barone, Francois Jamar, Willem H Bakker, Dik J Kwekkeboom, Hakim Bouterfa, Eric P Krenning. Semin Nucl Med 2006
210
100

Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy.
Daphne M V Huizing, Else A Aalbersberg, Michelle W J Versleijen, Margot E T Tesselaar, Iris Walraven, Max J Lahaye, Berlinda J de Wit-van der Veen, Marcel P M Stokkel. Cancer Imaging 2020
9
100

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Anja Rinke, Hans-Helge Müller, Carmen Schade-Brittinger, Klaus-Jochen Klose, Peter Barth, Matthias Wied, Christina Mayer, Behnaz Aminossadati, Ulrich-Frank Pape, Michael Bläker,[...]. J Clin Oncol 2009
100

Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy.
Elizabeth J Hamson, Fiona M Keane, Stefan Tholen, Oliver Schilling, Mark D Gorrell. Proteomics Clin Appl 2014
118
100

177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment.
Madhav Prasad Yadav, Sanjana Ballal, Madhavi Tripathi, Nishikant Avinash Damle, Ranjit Kumar Sahoo, Amlesh Seth, Chandrasekhar Bal. Eur J Nucl Med Mol Imaging 2017
94
100

Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer.
Stefano Fanti, Karolien Goffin, Boris A Hadaschik, Ken Herrmann, Tobias Maurer, Steven MacLennan, Daniela E Oprea-Lager, Wim Jg Oyen, Olivier Rouvière, Nicolas Mottet,[...]. Eur J Nucl Med Mol Imaging 2021
28
100

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
100

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617.
Justin Ferdinandus, Elisabeth Eppard, Florian C Gaertner, Stefan Kürpig, Rolf Fimmers, Anna Yordanova, Stefan Hauser, Georg Feldmann, Markus Essler, Hojjat Ahmadzadehfar. J Nucl Med 2017
69
100

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
Jonathan Strosberg, Ghassan El-Haddad, Edward Wolin, Andrew Hendifar, James Yao, Beth Chasen, Erik Mittra, Pamela L Kunz, Matthew H Kulke, Heather Jacene,[...]. N Engl J Med 2017
100

Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer.
Anna Yordanova, Paula Linden, Stefan Hauser, Michael Meisenheimer, Stefan Kürpig, Georg Feldmann, Florian C Gaertner, Markus Essler, Hojjat Ahmadzadehfar. Eur J Nucl Med Mol Imaging 2019
29
100

90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas.
Karine Gerster-Gilliéron, Flavio Forrer, Helmut Maecke, Jan Mueller-Brand, Adrian Merlo, Dominik Cordier. J Nucl Med 2015
21
100

PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013.
Harshad R Kulkarni, Aviral Singh, Christiane Schuchardt, Karin Niepsch, Manal Sayeg, Yevgeniy Leshch, Hans-Juergen Wester, Richard P Baum. J Nucl Med 2016
108
100

Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein.
Thomas Lindner, Anastasia Loktev, Annette Altmann, Frederik Giesel, Clemens Kratochwil, Jürgen Debus, Dirk Jäger, Walter Mier, Uwe Haberkorn. J Nucl Med 2018
164
100

Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.
L Bodei, M Kidd, I M Modlin, S Severi, I Drozdov, S Nicolini, D J Kwekkeboom, E P Krenning, R P Baum, G Paganelli. Eur J Nucl Med Mol Imaging 2016
68
100

Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617.
Hojjat Ahmadzadehfar, Simone Wegen, Anna Yordanova, Rolf Fimmers, Stefan Kürpig, Elisabeth Eppard, Xiao Wei, Carl Schlenkhoff, Stefan Hauser, Markus Essler. Eur J Nucl Med Mol Imaging 2017
93
100

Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Andrew J Armstrong, Aseem Anand, Lars Edenbrandt, Eva Bondesson, Anders Bjartell, Anders Widmark, Cora N Sternberg, Roberto Pili, Helen Tuvesson, Örjan Nordle,[...]. JAMA Oncol 2018
43
100

Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.
Bernhard Grubmüller, Daniela Senn, Gero Kramer, Pascal Baltzer, David D'Andrea, Karl Hermann Grubmüller, Markus Mitterhauser, Harald Eidherr, Alexander R Haug, Wolfgang Wadsak,[...]. Eur J Nucl Med Mol Imaging 2019
51
100

Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.
Wolfgang P Fendler, Manuel Weber, Amir Iravani, Michael S Hofman, Jérémie Calais, Johannes Czernin, Harun Ilhan, Fred Saad, Eric J Small, Matthew R Smith,[...]. Clin Cancer Res 2019
77
100

PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.
Lisa Bodei, Mark S Kidd, Aviral Singh, Wouter A van der Zwan, Stefano Severi, Ignat A Drozdov, Anna Malczewska, Richard P Baum, Dik J Kwekkeboom, Giovanni Paganelli,[...]. Eur J Nucl Med Mol Imaging 2020
27
100

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide.
Dik J Kwekkeboom, Eric P Krenning, Klemens Scheidhauer, Val Lewington, Rachida Lebtahi, Ashley Grossman, Pavel Vitek, Anders Sundin, Ursula Plöckinger. Neuroendocrinology 2009
99
100

68Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study.
Wim van Boxtel, Susanne Lütje, Ilse C H van Engen-van Grunsven, Gerald W Verhaegh, Jack A Schalken, Marianne A Jonker, James Nagarajah, Martin Gotthardt, Carla M L van Herpen. Theranostics 2020
12
100

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
Haesun Choi, Chuslip Charnsangavej, Silvana C Faria, Homer A Macapinlac, Michael A Burgess, Shreyaskumar R Patel, Lei L Chen, Donald A Podoloff, Robert S Benjamin. J Clin Oncol 2007
100

111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden.
Thomas A Hope, Jeremie Calais, Li Zhang, William Dieckmann, Corina Millo. J Nucl Med 2019
24
100

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.
James C Yao, Manal Hassan, Alexandria Phan, Cecile Dagohoy, Colleen Leary, Jeannette E Mares, Eddie K Abdalla, Jason B Fleming, Jean-Nicolas Vauthey, Asif Rashid,[...]. J Clin Oncol 2008
100

Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE.
Claudia Ortega, Rebecca K S Wong, Josh Schaefferkoetter, Patrick Veit-Haibach, Sten Myrehaug, Rosalyn Juergens, David Laidley, Reut Anconina, Amy Liu, Ur Metser. J Nucl Med 2021
2
100

18F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results.
L M Mittlmeier, M Unterrainer, S Rodler, A Todica, N L Albert, C Burgard, C C Cyran, W G Kunz, J Ricke, P Bartenstein,[...]. Eur J Nucl Med Mol Imaging 2021
2
100

68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer.
Clemens Kratochwil, Paul Flechsig, Thomas Lindner, Labidi Abderrahim, Annette Altmann, Walter Mier, Sebastian Adeberg, Hendrik Rathke, Manuel Röhrich, Hauke Winter,[...]. J Nucl Med 2019
248
100

Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Martina Benešová, Martin Schäfer, Ulrike Bauder-Wüst, Ali Afshar-Oromieh, Clemens Kratochwil, Walter Mier, Uwe Haberkorn, Klaus Kopka, Matthias Eder. J Nucl Med 2015
257
100

German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.
Kambiz Rahbar, Hojjat Ahmadzadehfar, Clemens Kratochwil, Uwe Haberkorn, Michael Schäfers, Markus Essler, Richard P Baum, Harshad R Kulkarni, Matthias Schmidt, Alexander Drzezga,[...]. J Nucl Med 2017
405
100

Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma.
Philipp E Hartrampf, Heribert Hänscheid, Olivia Kertels, Andreas Schirbel, Michael C Kreissl, Michael Flentje, Reinhart A Sweeney, Andreas K Buck, Bülent Polat, Constantin Lapa. Clin Transl Radiat Oncol 2020
10
100


Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience.
Lino M Sawicki, Christian Buchbender, Johannes Boos, Markus Giessing, Johannes Ermert, Christina Antke, Gerald Antoch, Hubertus Hautzel. Eur J Nucl Med Mol Imaging 2017
48
100

Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617.
Justin Ferdinandus, John Violet, Shahneen Sandhu, Rodney J Hicks, Aravind S Ravi Kumar, Amir Iravani, Grace Kong, Tim Akhurst, Sue Ping Thang, Declan G Murphy,[...]. Eur J Nucl Med Mol Imaging 2020
42
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.